Skip to main content

Table 1 Baseline characteristics comparing patients with DOAC and VKA pretreatment

From: MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists

 DOAC pretreatment (N = 75)VKA pretreatment (N = 61)PConfirmed therapeutic DOAC (N = 35)Confirmed therapeutic VKA (N = 45)P
Clinical items
 Age (years)76 (67–82)81 (75–84)0.01076 (68–83)80 (74–84)0.117
 Body mass index (kg/m2)26.4 (22.9–29.4)25.8 (23.6–28.6)0.67427.0 (23.1–30.0)25.7 (23.7–29.3)0.376
 Sex (female)27/75 (36.0%)26/61 (42.6%)0.48213/35 (37.1%)20/45 (44.4%)0.648
 Preevent modified Rankin Scale0.5 (0–1)1 (0–2)0.3060 (0–1)1 (0–2)0.327
 Onset  0.398  0.407
  - Known34/75 (45.3%)36/61 (59.0%) 18/35 (51.4%)29/45 (64.4%) 
  - Wake-up14/75 (18.7%)7/61 (11.5%) 6/35 (17.1%)4/45 (8.9%) 
  - Unknown27/75 (36.0%)18/61 (29.5%) 11/35 (31.4%)12/45 (26.7%) 
 1st blood pressure, systolic160 (136–176)160 (146–182)0.318156 (135–178)159 (143–176)0.446
 1st blood pressure, diastolic79 (70–94)88 (73–100)0.08978 (69–92)87 (72–99)0.145
 1st Glucose (mmol/L)6.2 (5.5–7.4)6.5 (5.5–7.9)0.5006.3 (5.7–7.7)6.6 (5.6–7.9)0.773
 1st Cholesterol, total (mmol/L)4.4 (3.8–5.1)4.5 (4.0–5.3)0.2444.5 (3.8–5.3)4.5 (3.8–5.2)0.848
 1st Cholesterol, LDL (mmol/L)2.4 (1.9–3.2)2.4 (2.0–3.3)0.5702.4 (1.9–3.3)2.4 (2.1–3.4)0.587
 1st Creatinine (umol/L)87 (75–102)88 (72–105)0.66689 (75–101)86 (70–107)0.809
 NIHSS on admission3 (2–8)5 (1–10)0.6974.5 (2–8.5)5 (1–12)0.996
Medication
 Additional Antiplatelet11/75 (14.7%)11/61 (18.3%)0.6423/35 (8.6%)9/45 (20%)0.210
 Lipid lowering drug31/75 (41.3%)26/61 (42.6%)0.66116/35 (45.7%)22/45 (48.9%)0.824
 Anticoagulation      
  - Confirmed therapeutic35/75 (46.7%)45/61 (73.8%)    
  - Uncertain30/75 (40%)0    
  - Confirmed non-therapeutic10/75 (13.3%)16/61 (26.2%)    
Risk factors
 Previous stroke22/75 (29.3%)14/61 (23.0%)0.62611/35 (31.4%)9/45 (20%)0.239
 Previous transient ischemic attack8/75 (10.7%)7/61 (11.5%)0.9136/35 (17.1%)6/45 (13.3%)0.454
 Arterial Hypertension62/75 (82.7%)53/61 (86.9%)0.69028/35 (90%)40/45 (88.9%)0.370
 Diabetes15/75 (20.0%)13/61 (21.3%)0.9577/35 (20%)9/45 (20%)0.984
 Hyperlipidemia46/75 (61.3%)41/61 (67.2%)0.62319/35 (54.3%)30/45 (66.7%)0.192
 Smoking15/75 (20.0%)4/61 (6.6%)0.0737/35 (20%)2/45 (4.4%)0.076
 Heart failure11/75 (14.7%)15/61 (24.6%)0.3285/35 (14.3%)11/45 (24.4%)0.296
 Atrial Fibrillation52/75 (69.3%)41/61 (67.2%)0.61723/35 (65.7%)31/45 (68.9%)0.764
 Mechanical Heart Valve04/61 (6.6%)0.09803/45 (6.7%)0.135
 Low Ejection Fraction (< 30%)2/75 (2.7%)1/61 (1.6%)0.6571/35 (2.9%)00.437
 Peripheral artery disease8/75 (10.7%)4/61 (6.6%)0.6773/35 (8.6%)4/45 (8.9%)0.983
Treatment
 Acute recanalization therapy  0.905  0.464
  - Intravenous thrombolysis2/75 (2.7%)1/61 (1.6%) 1/35 (2.9%)0 
  - Endovascular thrombectomy10/75 (13.3%)10/61 (16.4%) 3/35 (8.6%)6/45 (13.3%) 
  - Intraarterial thrombolysis1/75 (1.3%)1/61 (1.6%) 01/45 (2.2%) 
Imaging
 Fazekas Score1 (0–2)2 (1–3)< 0.0011 (0–2)2 (1–3)0.014
 Cerebral Microbleeds present28/72 (38.9%)27/57 (47.4%)0.37316/33 (48.5%)22/42 (52.4%)0.818
  1. DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, NIHSS National Institute of Health Stroke Scale